BOSTON—Amy Elazzouzi, Vice President of Finance at Aura Biosciences , Inc. (NASDAQ:AURA), not too long ago offered 1,001 shares of the corporate’s widespread inventory. The shares had been offered at a weighted common value of $7.6715, totaling roughly $7,679. The transaction comes as AURA trades at $7.93, with analysts setting a mean value goal of $20-23, suggesting vital upside potential in keeping with InvestingPro knowledge. This transaction was executed to cowl tax withholding obligations associated to the vesting of restricted inventory models. Following this sale, Elazzouzi holds 38,442 shares instantly. The sale was performed mechanically, not at Elazzouzi’s discretion, as a part of a pre-arranged plan. Aura Biosciences, a Boston-based biotechnology firm valued at $388 million, maintains a powerful liquidity place with a present ratio of 12.47 and more money than debt on its steadiness sheet. InvestingPro evaluation reveals 6 extra key insights about AURA’s monetary well being and development prospects.
This text was generated with the help of AI and reviewed by an editor. For extra data see our T&C.
By Kanishka Singh WASHINGTON (Reuters) - U.S. President Donald Trump's Council of Financial Advisers Chair…
The homeowners of New Look, the excessive avenue vogue chain, are ploughing £30m of recent…
Elon Musk has referred to as studies that he'll go away his authorities position within…
For many years, commerce and commerce coverage has been an financial and political backwater -…
President Trump on Wednesday laid out his long-awaited plans to slap reciprocal tariffs on nations…
Donald Trump has introduced a ten% commerce tariff on all imports from the UK -…